Comparison of different COVID-19 vaccines: messenger RNA, subunit, and attenuated vaccinedoi:10.1117/12.2660795ProteinsSafetyClinical trialsReceptorsGeneticsManufacturingVirusesMouse modelsStochastic processesT
Fig. 1. Current pre-and clinical trials of COVID-19 vaccines, according to World Health Organization (WHO) as of December 8, 2020. Out of 214 vaccine candidates, 52 are in clinical trials and 162 are in pre-clinical studies. The lead vaccine candidates target the SARS-CoV-2 spike (S)...
In comparison, a “susceptibility reducing” vaccine (Vaccine 2: moderate VESUSC, low VESYMP) with the same efficacy against COVID-19 disease (50% VEDIS) is expected to prevent additional 115,000 infections (17% more) and 1400 deaths (11% more) over 1 year (Fig.2, Vaccine 2). These ...
To provide a comprehensive understanding of these parameters, this meta-analysis aimed to estimate the pooled proportion of COVID-19 vaccine acceptance, hesitancy and perception in Cameroon. Methods A systematic search of online databases, including PubMed, Google Scholar, and ScienceDirect, was ...
Fig. 1: Comparison of COVID-19 VE and genetic mismatch across vaccine platforms. a, Distribution of the VE estimates for different platforms. The VE of mRNA and protein subunit vaccines are higher than other vaccines (two-sided ANOVA testP = 2.2 × 10−14,n = 78).b, ...
The next day, researchers around the world started work on a vaccine. By comparison, it took several months after the discovery of SARS in 2002 to sequence the full SARS-CoV-1 genetic code with the tools available at that time. The much faster timeline in the case of COVID-19 ...
Additionally, challenges in access to vaccines, lower socioeconomic areas, or countries with less advanced medical and health infrastructure, for example, means that a direct comparison of methodological processes and evaluations will also differ. Even assuming that vaccine dissemination goes as planned,...
三名研究人员独立寻找与COVID-19疫苗后免疫反应寿命相关的研究论文。PubMed和Scopus中的文章是使用以下搜索词选择的:“COVID-19 Vaccines”、“SARS-CoV-2 vaccine”、“2019-nCoV vaccine”、“2019-nCoV vaccines”、“immunity”、“immune process”、“immune Response”、“immunity”and “COVID 19 vaccine”...
and living environment)43. Participants were allocated to quintiles of deprivation based on their residential postcode. A valid COVID-19 vaccine dose was defined as a date of vaccination 14 days or more prior to the COVID-19 episode date. The Wild-type strain was dominant in the UK prior ...
(mean 64.6%) and Russia (mean 30.4%). Vaccine acceptance in LMICs is primarily explained by an interest in personal protection against COVID-19, while concern about side effects is the most common reason for hesitancy. Health workers are the most trusted sources of guidance about COVID-19 ...